Kardigan, Inc. (KARD) Stock Analysis & Investment Frameworks
Kardigan, Inc. (KARD) stock analysis on Invetso. Review Kardigan, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Kardigan, Inc. Company Overview
- Exchange: NASDAQ
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Kardigan, Inc. Key Financial Metrics
- Market Cap: $1.13B
- Revenue: $N/A
- ROE: -109.44%
- ROIC: -20.43%
- Dividend Yield: N/A
About Kardigan, Inc.
Kardigan, Inc. is a clinical-stage precision therapeutics company, which engages in developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. It combines clinical-stage drug programs with artificial intelligence, real-world patient data, and analytics through its “Cardiac Intelligence” platform to accelerate research and improve treatment outcomes. The company was founded by Tassos E. Gianakakos, Jay Edelberg, Bob McDowell, Leslie Leinwand, and Elizabeth McNally in August 2023 and is headquartered in Princeton, NJ.